Candida auris infections in ICU patients: risk factors, outcomes, and antifungal resistance patterns
Authors' conclusion
This study highlights the growing burden of Candida auris in intensive care unit settings, demonstrating a substantial incidence without increased mortality compared to non-auris Candida species.
Study context
- Population
- Adults (≥ 18 years) with culture-confirmed candidemia in the ICU of a tertiary care hospital in eastern India, January 2020-December 2023
- Participants
- 267 adults
- Exposure
- Candida auris vs non-auris Candida candidemia
- Candida aurisn = 38
- Outcome
- Incidence of Candida auris among ICU candidemia
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Candida auris
14.2%
38
Observational data: associations, not effects.
Further findings
Risk factors for Candida auris infection (multivariate analysis)
| OR | P value | |
|---|---|---|
| Increasing ageIndependently associated | 1.10 | P = 0.0003 |
| Female sexIndependently associated | 16.35 | P = 0.012 |
Age
ICU mortality · did not differ significantly
P = 0.854
Median
| Outcome | Candida auris | Non-auris | P value |
|---|---|---|---|
| SOFA score at admission | 7 | 8 | P = 0.02 |
| Survival (Kaplan-Meier)No statistically significant difference | log-rank p = 0.07 |
- Antifungal resistance in Candida auris isolates
- 94.7% · Fluconazole resistance · Amphotericin B resistance 39.5% · Echinocandin resistance 7.9%
Original publication
Candida auris infections in ICU patients: risk factors, outcomes, and antifungal resistance patterns. Crit Care. Published 28 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →